Janux Therapeutics Stock Forum

$Merck & Co (MRK.US)$ on the prowl for acquisitions up to $15 billion.
$Merck & Co (MRK.US)$ already has an active partnership with $Janux Therapeutics (JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF (XBI.US)$ in which $Merck & Co (MRK.US)$ already has a seat at the table.
$Merck & Co (MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...

$Janux Therapeutics (JANX.US)$ we need some hype guys! 🚀

$Janux Therapeutics (JANX.US)$  can someone explain why this stock has dropped so much? any news ?

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

$Janux Therapeutics (JANX.US)$ any comments about current performance?

$Janux Therapeutics (JANX.US)$ ...the hottest stock this year

Hello Mooers!
A quick recap for the month ending April 30, 2024.
Ten stocks with >300% YTD
$Swvl Holdings (SWVL.US)$718.40%
$Root Inc (ROOT.US)$564.60%
$Elevation Oncology (ELEV.US)$561.08%
$JanOne (JAN.US)$554.05%
$GeneDx Holdings (WGS.US)$520.71%
$Corbus Pharmaceuticals (CRBP.US)$513.25%
$AGBA Group (AGBA.US)$482.90%
$Janux Therapeutics (JANX.US)$431.22%
$Dave Inc (DAVE.US)$4...

RECAP
The $Dow Jones Industrial Average (.DJI.US)$ shed some 500 points and the $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ both fell more than 1% Friday as Dow components JPMorgan Chase and Intel dragged the market lower.
The DJIA shed 470.78 points (1.2%) to a preliminary 37988.3 closer, while the $S&P 500 Index (.SPX.US)$ gave up 75.46 ticks (1.5%) to a tentative 5,123.6 finish.
Meanwhile, the $Nasdaq Composite Index (.IXIC.US)$ -- which ...

$Janux Therapeutics (JANX.US)$ shares climbed for a fifth straight session, poised for a 45% gain this week, after Bloomberg reported that the drugmaker is exploring options, including a potential sale, after receiving takeover interest from larger pharmaceutical companies.
The company, which develops tumor-activated immunotherapies to treat cancer, is working with a financial adviser to evaluate possibilities including a sale, Blo...

$Janux Therapeutics (JANX.US)$ rallied more than 10% for the second straight session Thursday as investors continued to bid up the biotech amid a report that the company might be up for sale.
JANX rose 12.1% to $50 a share one day after gaining 11.5% on Wednesday following a Bloomberg News report about the potential sale of the firm, which develops anti-cancer drugs.
The news service cited unnamed sources as saying that Janu...